Functional Dyspepsia – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

 

Functional dyspepsia, a chronic disorder affecting sensation and peristalsis in the upper digestive tract, entails abnormal movement in the esophagus, stomach, and small intestine after swallowing. It is more prevalent among women, owing to inherent gender-specific differences in gastrointestinal function. The disrupted motility in functional dyspepsia leads to heightened sensations in the upper gut (visceral hyperalgesia). This results from disorganized and often ineffective emptying of the upper digestive tract, resulting in pain, fullness, bloating, and difficulty finishing meals. Common accompanying symptoms include heartburn, a sour taste in the mouth, excessive burping, nausea, and occasional vomiting. Understanding the exact mechanism behind functional dyspepsia remains elusive, as its pathophysiology is intricate. Various mechanisms are believed to contribute to each subtype. Traditionally, disturbances in gastric physiological factors have been divided into macroscopic and microscopic mechanisms.

Macroscopic mechanisms encompass:

• Gastroesophageal reflux (GERD)
• Delayed gastric emptying, rapid gastric emptying, gastric dysrhythmias, and antral hypomotility
• Visceral hypersensitivity with nervous system alterations

Microscopic mechanisms encompass:

• Impaired barrier function
• Gastroduodenal inflammation
• Altered gut microbiome and Helicobacter pylori infection

Two primary medication-based approaches to treating functional dyspepsia involve neutralizing acid and inhibiting its production. Histamine-2 receptor antagonists (H2RAs) and proton pump inhibitors (PPIs) are two drugs that reduce acid secretion. It's crucial to consider conditions like GERD, H. pylori infection, gastritis, peptic ulcer disease, and celiac disease as potential differential diagnoses. Functional dyspepsia, the leading cause of dyspeptic symptoms, accounts for 8 out of 10 cases of indigestion.

• Globally, approximately 7 in every 100 individuals suffer from functional dyspepsia, with a slightly higher prevalence in adults aged 18 to 39 compared to older age groups.

Thelansis’s “Functional Dyspepsia Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Functional Dyspepsia treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

KOLs insights of Functional Dyspepsia across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.

Functional Dyspepsia Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.

Thelansis Competitive Intelligence (CI) practice has been established based on a deep understanding of the pharma/biotech business environment to provide an optimized support system to all levels of the decision-making process. It enables business leaders in forward-thinking and proactive decision-making. Thelansis supports scientific and commercial teams in seamless CI support by creating an AI/ ML-based technology-driven platform that manages the data flow from primary and secondary sources.

Read more: Functional Dyspepsia – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033